@pmyhre Profile picture

Peder L. Myhre MD, PhD

@pmyhre

Professor of Cardiology @UniOslo_MED 🇳🇴 | Director @NorTrials Cardiovascular Center | @Brighamfellows alumni | Circulation On The Run podcast host @CircAHA |

Similar User
Muthu Vaduganathan photo

@mvaduganathan

Ankeet S. Bhatt, MD, MBA photo

@ankeetbhatt

Frederik H. Verbrugge photo

@FH_Verbrugge

BiykemBozkurt photo

@BiykemB

James Januzzi Jr MD photo

@JJheart_doc

Jonathan Davis, MD, MPHS photo

@JonathanDavisHF

Shelley Zieroth photo

@ShelleyZieroth

Marat Fudim, MD MHS photo

@FudimMarat

Faiez ZANNAD photo

@FaiezZANNAD

Steve Greene photo

@SJGreene_md

Thor Edvardsen photo

@ThorEdvardsen

Rachna Kataria, MD photo

@rachkataria

Giuseppe Galati photo

@GiuseppeGalati_

Gianluigi Savarese photo

@GianluSava

Sara Moscatelli photo

@saramoscatelli7

Peder L. Myhre MD, PhD Reposted

Multiple objective markers of HF and cardiorenal function improve with weight loss from tirzepatide in HFpEF. nature.com/articles/s4159…


Peder L. Myhre MD, PhD Reposted

🔴 BPROAD trial #AHA24 Intensive Blood-Pressure Control in Patients with Type 2 Diabetes 👥12821 type 2 diabetes 👉the incidence of major CV events was significantly ⬇️ with intensive 💊 targeting a SBP< 120 mm Hg 🆚 standard treatment targeting SBP<140 mm Hg 📁@nejm

Tweet Image 1

Peder L. Myhre MD, PhD Reposted

Join us for Updates in Heart Failure 2024 Congress - Stockholm - December 16-17th 2024. Also online! Free of charge! Register today and join the leading experts in HF! @Cardioinfo_it #cardiotwitter @_antocannata @HanCardiomd @KarolinskaUnsju heartfailurecongress.tmacademy.org

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Peder L. Myhre MD, PhD Reposted

Elevated #NT-proBNP and #hs-cTnI, but not #hs-cTnT, identifies future worsening of cardiac function in older adults free of CVD (ARIC study), suggesting greater cardiac specificity of cTnI vs cTnT @pmyhre @UniOslo @UTSWMedCenter @CBallantyneMD ahajournals.org/doi/abs/10.116…

Tweet Image 1

Peder L. Myhre MD, PhD Reposted

Thanks again for the invitation to present at the Norwegian Society of Cardiology! Great to see many friends including @BeitnesJan @pmyhre @ThorEdvardsen @dan_atar! Looking forward to collaborate on pragmatic RCTs very soon! And look at the beautiful venue for the meeting 👇

We are so excited to have you @TorBiering as the key note speaker at the annual Norwegian Society of Cardiology meeting 🇳🇴🙌🏻



This is what it looks like when @TorBiering blows the minds 🤯 of Norwegian cardiologists at the the NCS annual meeting with the presentation “Pragmatic clinical trials; the secret behind the danish success” 🙌🏻🇩🇰🇳🇴

Tweet Image 1

We are so excited to have you @TorBiering as the key note speaker at the annual Norwegian Society of Cardiology meeting 🇳🇴🙌🏻

Leaving beautiful Palermo, Sicily, to visit @pmyhre and the rest of the Norwegian Society of Cardiology in Oslo. Looking forward to seeing good friends and to discuss how we can work together to improve the Scandinavian collaboration on Pragmatic RCT’s. @CTCPR_ @BiomedUCPH

Tweet Image 1


Peder L. Myhre MD, PhD Reposted

In HFrEF, coexisting CKD worsens outcomes and complicates treatment. Guidelines lack clarity, but recent trials show the safety and efficacy of HF therapies in CKD patients. SoTA in #HREV covers key interventions and therapies, including device-based (link.springer.com/article/10.100…).


Peder L. Myhre MD, PhD Reposted

Thanks @pmyhre for having @shaan_khurshid and me on @CircAHA on the Run. Was fun talking about our Weekend Warrior study! If anyone wants to hear it, here is the link: ahajournals.org/do/10.1161/pod…


Peder L. Myhre MD, PhD Reposted

In this Viewpoint, now out in @JAMACardio, @johnwmcevoy @kazemr and I argue that risk thresholds to allocated CV prevention therapies should not be stratified by age. Link: jamanetwork.com/journals/jamac… Thread/

Tweet Image 1

Peder L. Myhre MD, PhD Reposted

Emerging research highlights the role of lymphatic dysfunction in HF, offering new therapeutic targets. Exciting advancements in lymphangiogenesis & molecular therapies may change HF management (link.springer.com/article/10.100…). #HREV @JanBiegus @FudimMarat


Peder L. Myhre MD, PhD Reposted

Despite strong evidence, use of SGLT2i in hospitalized HF patients remains slow due to concerns about DKA, hypoglycemia, and eGFR declines. SoTA review in #HREV on in-hospital SGLT2i safety & early use: (link.springer.com/article/10.100…). @SJGreene_md @ShahzebKhanMD @gcfmd @JavedButler1


Peder L. Myhre MD, PhD Reposted

Bradycardia and Pacemakers In Cross-Country Skiers @UU_University @CardioKasper @drsundstrom ahajournals.org/doi/full/10.11…

Tweet Image 1

Peder L. Myhre MD, PhD Reposted

And that’s a wrap! Thank you to the 275 attendees from 43 countries and the amazing faculty at the #proCardio, THE global cardiovascular forum. What a smashing success. #proCardioforum

Tweet Image 1

Last session of #proCardioForum was the cherry on the cake: 🔥Hot Topics and Unmet Needs🔥 by the Kings and Queens in each field: 👑Amyloid: @dr_m_fontana 👑HCM: @IacopoOlivotto 👑DM: @ambarish4786 👑CRM: @mvaduganathan

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Peder L. Myhre MD, PhD Reposted

Time for hot topics 🔥at #procardioforum Professor Marianna Fontana (@dr_m_fontana) speaking on evolution of diagnosis and treatment of cardiac amyloidosis.

Tweet Image 1

Straight from the bar 😵🍻

Teaching the Europeans how to run 🇳🇴 🏴󠁧󠁢󠁳󠁣󠁴󠁿 🇺🇸 🇩🇰 👊🏼👊🏼 👊🏾👊🏼 Banks of the Rhine, Basel, Switzerland #proCardio2024

Tweet Image 1


I am blown away be the high level of the presentations at #proCardio symposium led by @JJheart_doc 🙌🏻 All star line-up this morning: Obesity by #NaveedSattar Lp(a) by @CBallantyneMD HF screening by @safchat …and more to come!

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Peder L. Myhre MD, PhD Reposted

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in HFmrEF/HFpEF: a Prespecified Analysis of The FINEARTS-HF Trial Now online @CircAHA after presentation at #HFSA2024 Consistent benefit of finerenone regardless of LVEF ahajournals.org/doi/10.1161/CI…


Loading...

Something went wrong.


Something went wrong.